Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND ACETAMINOPHEN versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND ACETAMINOPHEN versus QDOLO.
HYDROCODONE BITARTRATE AND ACETAMINOPHEN vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Oral: 1-2 tablets (5-10 mg hydrocodone/325-650 mg acetaminophen) every 4-6 hours as needed for pain; maximum daily doses: hydrocodone 40 mg, acetaminophen 3000 mg.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Hydrocodone: 3.8-7.4 hours (terminal), prolonged in hepatic impairment. Acetaminophen: 1.5-2.5 hours (terminal).
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal excretion of metabolites (hydrocodone: ~60% as conjugates, <12% unchanged; acetaminophen: ~85-90% as glucuronide and sulfate conjugates, <5% unchanged). Biliary/fecal elimination of minor metabolites.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist